One-year real-world effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: analysis from the BADBIR

被引：0
|
作者：
Savage, Laura [1 ]
Wang, Xiayi [2 ]
Johnson, David [3 ]
Gillespie, Justin [3 ]
机构：
[1] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[2] Janssen Cilag, Raritan, NJ USA
[3] Janssen Cilag, High Wycombe, Bucks, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P88
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [1] Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
    Galluzzo, Marco
    Talamonti, Marina
    Bernardini, Nicoletta
    Chiricozzi, Andrea
    De Simone, Clara
    Bonifati, Claudio
    Bruni, Pierluigi
    Diotallevi, Federico
    Esposito, Maria
    Graceffa, Dario
    Hansel, Katharina
    Loconsole, Francesco
    Moretta, Gaia
    Mugheddu, Cristina
    Papini, Manuela
    Richetta, Antonio
    Skroza, Nevena
    Atzori, Laura
    Fargnoli, Maria Concetta
    Persechino, Severino
    Offidani, Annamaria
    Stingeni, Luca
    Peris, Ketty
    Potenza, Concetta
    Bianchi, Luca
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1585 - 1592
  • [2] Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
    April W. Armstrong
    Timothy Fitzgerald
    Robert R. McLean
    Amanda Teeple
    Jonathan P. Uy
    Mobolaji Olurinde
    Katelyn Rowland
    Lin Guo
    Ying Shan
    Kristina Callis Duffin
    [J]. Dermatology and Therapy, 2023, 13 : 629 - 640
  • [3] Real-world effectiveness of guselkumab in achieving absolute PASI thresholds and mean DLQI scores in patients with moderate-to-severe plaque psoriasis: analysis of the BADBIR registry following 6 months of treatment
    Gillespie, J.
    Johnson, D.
    Wang, X.
    Sjoeland, E.
    Hampton, Kathryn
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 : 59 - 59
  • [4] Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab
    Cazana, Tamara Gracia
    Monroig, Josep Riera
    Izu, Rosa
    Yanguas, Ignacio
    Espes, Marta Lorda
    Salas, Maria Pilar Sanchez
    Gil, Miguel Fernando Garcia
    Bielsa, Alba Navarro
    Manrique, Beatriz Aldea
    Blasco, Manuel Almenara
    de Aranibar, Francisco Javier Garcia-Latasa
    Fuentelsaz, Victoria
    Callaghan, Ana Morales
    Ara-Martin, Mariano
    [J]. JAAD INTERNATIONAL, 2024, 16 : 66 - 71
  • [5] Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
    Armstrong, April W. W.
    Fitzgerald, Timothy
    McLean, Robert R. R.
    Teeple, Amanda
    Uy, Jonathan P. P.
    Olurinde, Mobolaji
    Rowland, Katelyn
    Guo, Lin
    Shan, Ying
    Duffin, Kristina Callis
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (02) : 629 - 640
  • [6] Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
    Hung, Yi-Teng
    Lin, Yu-, Jr.
    Chiu, Hsien-Yi
    Huang, Yu-Huei
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12
  • [7] Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study
    Puig, L.
    Dauden, E.
    Cuervas-Mons, M.
    Novella, C.
    Guisado, C.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023,
  • [8] Effectiveness of guselkumab among patients with moderate-to-severe plaque psoriasis in the Corrona Psoriasis Registry
    Armstrong, April W.
    Callis-Duffin, Kristina
    Fitzgerald, Timothy
    Teeple, Amanda
    Uy, Jonathan
    Olurinde, Mobolaji
    Rowland, Katelyn
    McLean, Robert R.
    Guo, Lin
    Shan, Ying
    Van Voorhees, Abby S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB122 - AB122
  • [9] REAL-WORLD EFFECTIVENESS AND SAFETY IN A PHASE 4 STUDY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Bhatia, N.
    Vasquez, J. G.
    Schenkel, B.
    Rozzo, S. J.
    Heim, J.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S57 - S57
  • [10] Guselkumab in the treatment of moderate-to-severe plaque psoriasis
    Lopez-Sanchez, Cristina
    Puig, Lluis
    [J]. IMMUNOTHERAPY, 2020, 12 (06) : 355 - 371
12345